Listed as part of the 2022 Southeast Asia Health Tech 50
Nov 7, 2022 – Axcynsis Therapeutics has been selected to be part of HolonIQ’s annual list of 2022 Southeast Asia Health Tech 50.
This annual list features the most promising startups from across digital health, biotech, medtech and other areas where entrepreneurs are driving healthcare innovation.
“We are honoured to be selected as part of the 2022 Southeast Asia Health Tech 50,” says Dr Zou, CEO of Axcynsis Therapeutics. “We are very encouraged by this recognition, and we will continue to strive and achieve excellence to develop the best-in-class and first-in-class Antibody-X conjugates to address unmet medical needs.”
About Axcynsis Therapeutics Pte. Ltd.
Axcynsis Therapeutics Pte. Ltd. is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprietary technologies, we are developing a robust pipeline of AXC candidates with the potential to address unmet medical needs for new treatment options.
For all media queries, please contact:
Wong Yun Xuan